$AKTX
Akari Therapeutics Plc

2024 Q3 Form 10-Q Financial Statement

#000095017024098576 Filed on August 19, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.709M $2.241M $5.954M
YoY Change -39.42% -62.36% 100.82%
% of Gross Profit
Research & Development $143.0K $3.314M $3.255M
YoY Change -145.54% 1.81% 14.17%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $1.850K
YoY Change -100.0% 96.81%
% of Gross Profit
Operating Expenses $1.852M $5.555M $9.210M
YoY Change -26.13% -39.68% 58.35%
Operating Profit -$2.927M -$7.449M -$4.615M
YoY Change 16.75% 61.41%
Interest Expense $2.000K $51.00K $86.61K
YoY Change -41.12% -40.43%
% of Operating Profit
Other Income/Expense, Net $32.00K -$109.0K $6.124M
YoY Change -108.79% -101.78% -66597.18%
Pretax Income -$2.895M -$7.558M -$2.999M
YoY Change 152.05% -47.21%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.895M -$7.558M -$2.999M
YoY Change 0.84% 152.05% -47.21%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 23.91B 15.85B 10.12B
Diluted Shares Outstanding 24.39B 18.84B 10.12B

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.246M $4.177M $7.181M
YoY Change -41.83% -11.91%
Cash & Equivalents $2.200M $4.200M $7.181M
Short-Term Investments
Other Short-Term Assets $92.00K $94.00K $816.5K
YoY Change -88.49% -74.49%
Inventory
Prepaid Expenses $396.0K $805.0K
Receivables
Other Receivables $0.00
Total Short-Term Assets $2.734M $5.076M $7.997M
YoY Change -36.53% -29.55%
LONG-TERM ASSETS
Property, Plant & Equipment $31.81K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $11.14K
YoY Change
Total Long-Term Assets $0.00 $0.00 $15.78K
YoY Change -100.0% -16.24%
TOTAL ASSETS
Total Short-Term Assets $2.734M $5.076M $7.997M
Total Long-Term Assets $0.00 $0.00 $15.78K
Total Assets $2.734M $5.076M $8.013M
YoY Change -36.65% -29.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.782M $4.686M $1.031M
YoY Change 354.68% -36.96%
Accrued Expenses $2.605M $1.685M $2.402M
YoY Change -29.85% 70.29%
Deferred Revenue
YoY Change
Short-Term Debt $200.0K $600.0K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.428M $8.779M $5.232M
YoY Change 67.81% 71.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $9.428M $8.779M $5.232M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $9.428M $8.779M $5.232M
YoY Change 67.81% 71.79%
SHAREHOLDERS EQUITY
Retained Earnings -$243.5M -$240.6M
YoY Change
Common Stock $185.5M $185.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.694M -$3.703M $2.781M
YoY Change
Total Liabilities & Shareholders Equity $2.734M $5.076M $8.013M
YoY Change -36.65% -29.53%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$2.895M -$7.558M -$2.999M
YoY Change 0.84% 152.05% -47.21%
Depreciation, Depletion And Amortization $0.00 $0.00 $1.850K
YoY Change -100.0% 96.81%
Cash From Operating Activities -$1.490M -$4.894M -$9.574M
YoY Change -48.88% 11.66%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $3.503M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -443.0K 7.763M 3.503M
YoY Change 121.62%
NET CHANGE
Cash From Operating Activities -1.490M -4.894M -9.574M
Cash From Investing Activities
Cash From Financing Activities -443.0K 7.763M 3.503M
Net Change In Cash -1.933M 2.869M -6.071M
YoY Change -147.26% -29.19%
FREE CASH FLOW
Cash From Operating Activities -$1.490M -$4.894M -$9.574M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 aktx Deferred Shares Issued
DeferredSharesIssued
3847331913
CY2020Q4 aktx Deferred Shares Issued Price Per Share
DeferredSharesIssuedPricePerShare
0.01315
CY2020Q4 aktx Aggregate Nominal Value Cancelled Per Share
AggregateNominalValueCancelledPerShare
0.01
CY2020Q4 aktx Aggregate Nominal Value Cancelled
AggregateNominalValueCancelled
50600000
CY2020Q4 aktx Capital Redemption Reserve
CapitalRedemptionReserve
50600000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.98
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.993
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.043
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.038
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001541157
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36288
dei Entity Registrant Name
EntityRegistrantName
Akari Therapeutics, Plc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1034922
dei Entity Address Address Line1
EntityAddressAddressLine1
22 Boston Wharf Road
dei Entity Address Address Line2
EntityAddressAddressLine2
FL 7
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02210
dei City Area Code
CityAreaCode
929
dei Local Phone Number
LocalPhoneNumber
274-7510
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23906899523
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4177000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3845000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
805000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
299000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
94000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
197000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
5076000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4341000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
14000
CY2024Q2 us-gaap Assets
Assets
5076000
CY2023Q4 us-gaap Assets
Assets
4355000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4686000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1671000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1685000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1566000
CY2024Q2 aktx Convertible Debt Related Party
ConvertibleDebtRelatedParty
1000000
CY2024Q2 aktx Warrant Liabilities Current
WarrantLiabilitiesCurrent
755000
CY2023Q4 aktx Warrant Liabilities Current
WarrantLiabilitiesCurrent
1253000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
653000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
94000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
8779000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4584000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
45122321523
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
45122321523
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24289232698
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24289232698
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13234315298
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13234315298
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
2430000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1324000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
183007000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
174754000
CY2024Q2 aktx Capital Redemption Reserve
CapitalRedemptionReserve
52194000
CY2023Q4 aktx Capital Redemption Reserve
CapitalRedemptionReserve
52194000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-749000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1040000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-240585000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-227461000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-3703000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-229000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5076000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4355000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3314000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1524000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5593000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3255000
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2241000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3091000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4907000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5954000
CY2024Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
254000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1298000
CY2024Q2 us-gaap Restructuring Costs
RestructuringCosts
1640000
us-gaap Restructuring Costs
RestructuringCosts
1640000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7449000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4615000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13438000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9209000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
29000
us-gaap Investment Income Interest
InvestmentIncomeInterest
4000
us-gaap Investment Income Interest
InvestmentIncomeInterest
59000
CY2024Q2 us-gaap Interest Expense
InterestExpense
51000
us-gaap Interest Expense
InterestExpense
51000
CY2024Q2 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-151000
CY2023Q2 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
560000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
498000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
6147000
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
91000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
39000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-135000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
28000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-24000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-109000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
615000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
314000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6210000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7558000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4000000
us-gaap Net Income Loss
NetIncomeLoss
-13124000
us-gaap Net Income Loss
NetIncomeLoss
-2999000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18836478977
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18836478977
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10115005727
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10115005727
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16144813478
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16144813478
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8787337361
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8787337361
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7558000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4000000
us-gaap Net Income Loss
NetIncomeLoss
-13124000
us-gaap Net Income Loss
NetIncomeLoss
-2999000
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
12000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-57000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
291000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-55000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
12000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-57000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
291000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-55000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7546000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4057000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12833000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3054000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-229000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1664000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
3000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
296000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
279000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-5566000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-3553000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6951000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
445000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
12000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7558000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-3703000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1791000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3502000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
265000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
2000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
1001000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
6561000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
1000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
276000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-57000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4000000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2781000
us-gaap Net Income Loss
NetIncomeLoss
-13124000
us-gaap Net Income Loss
NetIncomeLoss
-2999000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2000
us-gaap Share Based Compensation
ShareBasedCompensation
741000
us-gaap Share Based Compensation
ShareBasedCompensation
541000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
498000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
6147000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-280000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
34000
aktx Increase Decrease In Accounts Receivables And Prepaid Expense
IncreaseDecreaseInAccountsReceivablesAndPrepaidExpense
-702000
aktx Increase Decrease In Accounts Receivables And Prepaid Expense
IncreaseDecreaseInAccountsReceivablesAndPrepaidExpense
269000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2948000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-668000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8938000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9574000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8820000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3502000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1000000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
3000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
546000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9277000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3503000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-7000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
332000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6069000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3845000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13250000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4177000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7181000
aktx Financing Costs In Accrued Expenses
FinancingCostsInAccruedExpenses
205000
aktx Non Cash Seller Financed Purchases
NonCashSellerFinancedPurchases
1105000
us-gaap Interest Paid Net
InterestPaidNet
51000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-240600000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4200000
aktx Stockholders Equity Requirement
StockholdersEquityRequirement
2500000
CY2023Q4 aktx Remaining Shareholders Deficit Required To Get Listed In Nasdaq Listing
RemainingShareholdersDeficitRequiredToGetListedInNasdaqListing
200000
CY2024Q2 aktx Remaining Shareholders Deficit Required To Get Listed In Nasdaq Listing
RemainingShareholdersDeficitRequiredToGetListedInNasdaqListing
3700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of estimates –</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets, liabilities, expenses and related disclosures. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the valuation of share-based awards, the valuation of warrant liabilities, research and development prepayments, accruals and related expenses, and the valuation allowance for deferred income taxes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed considering changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of credit risk</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">– </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash. The Company generally maintains balances in various operating accounts at financial institutions in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p>
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2024Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
1100000
CY2024Q1 us-gaap Short Term Debt Percentage Bearing Fixed Interest Rate
ShortTermDebtPercentageBearingFixedInterestRate
0.0749
CY2024Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
600000
us-gaap Short Term Debt Terms
ShortTermDebtTerms
monthly installments through November 2024.
CY2024Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
300000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1300000
CY2024Q2 aktx Restructuring And Related Cost Expected Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent
0.67
us-gaap Restructuring Charges
RestructuringCharges
1600000
CY2024Q2 aktx Restructuring Charges Unpaid
RestructuringChargesUnpaid
500000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15052693203
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5254040600
CY2024Q2 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
755000
CY2023Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
1253000
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1253000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-498000
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
755000
CY2024Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
377000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
187000
CY2024Q2 aktx Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
446000
CY2023Q4 aktx Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
635000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
363000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
669000
CY2024Q2 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
458000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
41000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
75000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1685000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1566000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
45122321523
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
45122321523
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
445000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
276000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
741000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
541000
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
us-gaap Operating Lease Cost
OperatingLeaseCost
200000
us-gaap Operating Lease Cost
OperatingLeaseCost
100000
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-098576-index-headers.html Edgar Link pending
0000950170-24-098576-index.html Edgar Link pending
0000950170-24-098576.txt Edgar Link pending
0000950170-24-098576-xbrl.zip Edgar Link pending
aktx-20240630.htm Edgar Link pending
aktx-20240630.xsd Edgar Link pending
aktx-ex10_3.htm Edgar Link pending
aktx-ex10_5.htm Edgar Link pending
aktx-ex31_1.htm Edgar Link pending
aktx-ex31_2.htm Edgar Link pending
aktx-ex32_1.htm Edgar Link pending
aktx-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
aktx-20240630_htm.xml Edgar Link completed
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending